Evidence map›Paper›PMID 26980738›Full record

ArticleOncotarget2016

Development of a new outcome prediction model for Chinese patients with penile squamous cell carcinoma based on preoperative serum C-reactive protein, body mass index, and standard pathological risk factors: the TNCB score group system.

Zai-Shang Li, Peng Chen, Kai Yao, Bin Wang, Jing Li, Qi-Wu Mi, Xiao-Feng Chen, Qi Zhao, Yong-Hong Li, Jie-Ping Chen and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Inflammation in Penile Squamous Cell Carcinoma: A Comprehensive Review.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Zai-Shang LiDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Peng ChenDepartment of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumchi, P. R. China.
Kai YaoDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Bin WangDepartment of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, P. R. China.
Jing LiDepartment of Urology, Cancer Center of Guangzhou Medical University, Guangzhou, P. R. China.
Qi-Wu MiDepartment of Urology, Dong Guan People's Hospital, Guang Dong, P. R. China.
Xiao-Feng ChenDepartment of Urology,The First People's Hospital of Chenzhou, Chenzhou, P. R. China.
Qi ZhaoSchool of Life Science, Sun Yat-sen University, School of Life Science, Guang Dong, P. R. China.
Yong-Hong LiDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Jie-Ping ChenDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Chuang-Zhong DengDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Yun-Lin YeDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Ming-Zhu ZhongDepartment of Urology, The People's Hospital of Jiangmen, Jiangmen, P. R. China.
Zhuo-Wei LiuDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Zi-Ke QinDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Xiang-Tian LinZhongshan School of Medicine, Sun Yat-sen University, Guang Dong, P. R. China.
Wei-Cong LiangZhongshan School of Medicine, Sun Yat-sen University, Guang Dong, P. R. China.
Hui HanDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Fang-Jian ZhouDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Sun Yat-sen University · CNSouthern Medical University · CNGuangzhou Medical University · CNChenzhou First People's Hospital · CNDongguan People’s Hospital · CNJiangmen Central Hospital · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the predictive value and feasibility of the new outcome prediction model for Chinese patients with penile squamous cell carcinoma.

resultsThe 3-year disease-specific survival (DSS) survival (DSS) was 92.3% in patients with < 8.70 mg/L CRP and 54.9% in those with elevated CRP (P < 0.001). The 3-year DSS was 86.5% in patients with a BMI < 22.6 Kg/m2 and 69.9% in those with a higher BMI (P = 0.025). In a multivariate analysis, pathological T stage (P < 0.001), pathological N stage (P = 0.002), BMI (P = 0.002), and CRP (P = 0.004) were independent predictors of DSS. A new scoring model was developed, consisting of BMI, CRP, and tumor T and N classification. In our study, we found that the addition of the above-mentioned parameters significantly increased the predictive accuracy of the system of the American Joint Committee on Cancer (AJCC) anatomic stage group. The accuracy of the new prediction category was verified.

methodsA total of 172 Chinese patients with penile squamous cell cancer were analyzed retrospectively between November 2005 and November 2014. Statistical data analysis was conducted using the nonparametric method. Survival analysis was performed with the log-rank test and the Cox proportional hazard model. Based on regression estimates of significant parameters in multivariate analysis, a new BMI-, CRP- and pathologic factors-based scoring model was developed to predict disease--specific outcomes. The predictive accuracy of the model was evaluated using the internal and external validation.

conclusionsThe present study demonstrated that the TNCB score group system maybe a precise and easy to use tool for predicting outcomes in Chinese penile squamous cell carcinoma patients.

Indexed as

Body Mass IndexAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellChinaC-Reactive ProteinFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedPenile NeoplasmsBiomarkers, TumorC-Reactive Proteinbody mass indexC-reactive proteinneoplasm stagingpenile neoplasmsprognosis

Identifiers

PMID26980738
PMCPMC4991509
OpenAlexW2299677099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.